Logo image of REVB

REVELATION BIOSCIENCES INC (REVB) Stock Fundamental Analysis

NASDAQ:REVB - Nasdaq - US76135L5075 - Common Stock - Currency: USD

4.31  -0.09 (-2.05%)

After market: 4.0293 -0.28 (-6.51%)

Fundamental Rating

1

Overall REVB gets a fundamental rating of 1 out of 10. We evaluated REVB against 572 industry peers in the Biotechnology industry. The financial health of REVB is average, but there are quite some concerns on its profitability. REVB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

REVB had negative earnings in the past year.
REVB had a negative operating cash flow in the past year.
REVB had negative earnings in each of the past 5 years.
REVB had a negative operating cash flow in each of the past 5 years.
REVB Yearly Net Income VS EBIT VS OCF VS FCFREVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of REVB (-230.20%) is worse than 91.83% of its industry peers.
REVB's Return On Equity of -580.33% is on the low side compared to the rest of the industry. REVB is outperformed by 81.35% of its industry peers.
Industry RankSector Rank
ROA -230.2%
ROE -580.33%
ROIC N/A
ROA(3y)-261.6%
ROA(5y)-171.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
REVB Yearly ROA, ROE, ROICREVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 2K 4K 6K 8K 10K

1.3 Margins

REVB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
REVB Yearly Profit, Operating, Gross MarginsREVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, REVB has more shares outstanding
REVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
REVB Yearly Shares OutstandingREVB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M
REVB Yearly Total Debt VS Total AssetsREVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

REVB has an Altman-Z score of -11.45. This is a bad value and indicates that REVB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -11.45, REVB is not doing good in the industry: 76.73% of the companies in the same industry are doing better.
REVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.45
ROIC/WACCN/A
WACCN/A
REVB Yearly LT Debt VS Equity VS FCFREVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 1.64 indicates that REVB should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.64, REVB is doing worse than 81.35% of the companies in the same industry.
A Quick Ratio of 1.64 indicates that REVB should not have too much problems paying its short term obligations.
REVB has a Quick ratio of 1.64. This is amonst the worse of the industry: REVB underperforms 80.28% of its industry peers.
Industry RankSector Rank
Current Ratio 1.64
Quick Ratio 1.64
REVB Yearly Current Assets VS Current LiabilitesREVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for REVB have decreased strongly by -1463.90% in the last year.
EPS 1Y (TTM)-1463.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -25.07% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1047.92%
EPS Next 2Y-62.11%
EPS Next 3Y-31.97%
EPS Next 5Y-25.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
REVB Yearly Revenue VS EstimatesREVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M 200M
REVB Yearly EPS VS EstimatesREVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5K -10K -15K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for REVB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for REVB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
REVB Price Earnings VS Forward Price EarningsREVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
REVB Per share dataREVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100

4.3 Compensation for Growth

REVB's earnings are expected to decrease with -31.97% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.11%
EPS Next 3Y-31.97%

More info and screens

0

5. Dividend

5.1 Amount

REVB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REVELATION BIOSCIENCES INC

NASDAQ:REVB (2/21/2025, 8:00:01 PM)

After market: 4.0293 -0.28 (-6.51%)

4.31

-0.09 (-2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/amc
Earnings (Next)03-20 2025-03-20/amc
Inst Owners6.81%
Inst Owner Change-100%
Ins Owners5.9%
Ins Owner Change1.56%
Market Cap2.24M
Analysts82.86
Price Target174.14 (3940.37%)
Short Float %N/A
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-53.82%
Min EPS beat(2)-178.64%
Max EPS beat(2)71%
EPS beat(4)3
Avg EPS beat(4)-2.93%
Min EPS beat(4)-178.64%
Max EPS beat(4)71%
EPS beat(8)6
Avg EPS beat(8)63.92%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1239.02%
PT rev (3m)1239.02%
EPS NQ rev (1m)-688.41%
EPS NQ rev (3m)-688.41%
EPS NY rev (1m)-6766.84%
EPS NY rev (3m)-4413.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.84
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)-143.21
EYN/A
EPS(NY)-34.71
Fwd EYN/A
FCF(TTM)-31.95
FCFYN/A
OCF(TTM)-31.88
OCFYN/A
SpS0
BVpS5.14
TBVpS5.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -230.2%
ROE -580.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-261.6%
ROA(5y)-171.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.64
Quick Ratio 1.64
Altman-Z -11.45
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1463.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
EPS Next Y-1047.92%
EPS Next 2Y-62.11%
EPS Next 3Y-31.97%
EPS Next 5Y-25.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-13.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-26.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.05%
OCF growth 3YN/A
OCF growth 5YN/A